Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy.

Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy.
复制标题

DOI:
10.3389/fonc.2021.749496
复制
发表时间:
2021
影响因子:
4.7
通讯作者:
Fishel ML
Fishel ML
中科院分区:
医学3区
文献类型:
--
作者:
Elbanna M;Chowdhury NN;Rhome R;Fishel ML

文献摘要

参考文献

被引文献

相似文献

在精准医学时代,放射医学目前的重点是精确实施高度适形的放射治疗。然而,靶向治疗的巨大发展尚未兑现其全部承诺,并且可以说有潜力显着提高放射治疗比率。在诊断和复发时对肿瘤进行分子分析的能力增强,以及放射基因组学领域的同步进展,可能为更加个性化的放射治疗方法铺平道路,这与当前的“一刀切”范式形成鲜明对比。迄今为止,很少有临床试验显示靶向药物与放射治疗相结合可改善临床结果,但大多数试验未能显示出益处,这可能是由于临床前数据有限。理论上,当通过直接增强肿瘤细胞杀伤或与新型免疫疗法相结合时通过辐射的远隔效应间接地合理靶向时,几个关键的分子途径可以增强辐射的治疗效果。分子靶向治疗与放射治疗相结合的时机也很重要,并且可能会极大地影响结果,具体取决于哪种途径被抑制。
In the era of precision medicine, radiation medicine is currently focused on the precise delivery of highly conformal radiation treatments. However, the tremendous developments in targeted therapy are yet to fulfill their full promise and arguably have the potential to dramatically enhance the radiation therapeutic ratio. The increased ability to molecularly profile tumors both at diagnosis and at relapse and the co-incident progress in the field of radiogenomics could potentially pave the way for a more personalized approach to radiation treatment in contrast to the current ‘‘one size fits all’’ paradigm. Few clinical trials to date have shown an improved clinical outcome when combining targeted agents with radiation therapy, however, most have failed to show benefit, which is arguably due to limited preclinical data. Several key molecular pathways could theoretically enhance therapeutic effect of radiation when rationally targeted either by directly enhancing tumor cell kill or indirectly through the abscopal effect of radiation when combined with novel immunotherapies. The timing of combining molecular targeted therapy with radiation is also important to determine and could greatly affect the outcome depending on which pathway is being inhibited.
DOI: 10.1016/s1470-2045(14)71207-0
发表时间: 2015-02
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Bradley, Jeffrey D.;Paulus, Rebecca;Komaki, Ritsuko;Masters, Gregory;Blumenschein, George;Schild, Steven;Bogart, Jeffrey;Hu, Chen;Forster, Kenneth;Magliocco, Anthony;Kavadi, Vivek;Garces, Yolanda I.;Narayan, Samir;Iyengar, Puneeth;Robinson, Cliff;Wynn, Raymond B.;Koprowski, Christopher;Meng, Joanne;Beitler, Jonathan;Gaur, Rakesh;Curran, Walter, Jr.;Choy, Hak
通讯作者: Choy, Hak
DOI: 10.3109/0284186x.2014.992547
发表时间: 2015-01-01
期刊: ACTA ONCOLOGICA
影响因子: 3.1
作者:
Bentzen, Jens;Toustrup, Kasper;Overgaard, Jens
通讯作者: Overgaard, Jens
DOI: 10.1080/09553002.2018.1558299
发表时间: 2019-04-01
影响因子: 2.6
作者:
Boysen, Gunnar;Jamshidi-Parsian, Azemat;Griffin, Robert J.
通讯作者: Griffin, Robert J.
DOI: 10.1158/1078-0432.ccr-18-2466
发表时间: 2019-03-01
影响因子: 11.5
作者:
Ahmad, Saif S.;Crittenden, Marka R.;Sharma, Ricky A.
通讯作者: Sharma, Ricky A.
DOI: 10.1016/s1470-2045(21)00149-2
发表时间: 2021-06-01
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Altorki, Nasser K.;McGraw, Timothy E.;Formenti, Silvia C.
通讯作者: Formenti, Silvia C.